Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients

Table 2 Univariate regression modelling KRECs and TRECs change from T0 to T72

	T72-T0 log KRECs/mL difference	T72-T0 log TRECs/mL difference
	coefficient	coefficient
log KRECs/mL at T0	−0.39 [−0.795,0.0155]*	n.i.
log TRECs/mL at T0	n.i.	−0.67 [−0.826,−0.514]‡
Age at T0	0.000488 [−0.0297,0.0307]	0.00908 [−0.0367,0.0549]
Viremia at T0 (log DNAcopies/mL)	0.07 [−0.136,0.276]	−0.0774 [−0.378,0.223]
CD4 at T0 (cells/mL)	0.000225 [−0.00117,0.00162]	−0.00171 [−0.00363,0.000212]*
CD4/CD8 at T0	0.548 [−0.451,1.55]	−1.88 [−3.18,−0.585]†
Therapy arm	0.156 [−0.196,0.507]	−0.0792 [−0.594,0.435]
Infection duration before therapy start (years)	−0.105 [−0.163,−0.0471]†	−0.0753 [−0.172,0.0217]
HCV coinfection	−0.131 [−0.634,0.372]	−0.470 [−1.141,0.200]

95% confidence intervals are in square brackets; n.i.: not included in the model; * p <0.10; † p <0.01; ‡ p <0.001.

ISSN: 1479-5876